Blog Index
The journal that this archive was targeting has been deleted. Please update your configuration.


Clarentis Technologies is actively pursuing partnerships with medical companies to develop new applications for its electrochemically activated solutions.

In October 2010, the company signed an agreement with Hydroionx for use of its disinfectant in facilities, laboratories and clean rooms (including instruments and equipment) and the development of special solutions targeting:

  • organs
  • eyes
  • research and issue banking “human and animal organs"
  • tissue
  • cell transplantation including allograft, autograft, xenograft any combinations thereof 

Clarentis Technologies is actively pursuing applications that include: 

  • microcidal rinse during surgery
  • topical gel for woundcare and treatment of burns
  • wound treatment 
  • treatment of venous ulcers
  • preservation of tissue culture
  • liquids for nebulizers, IV solutions, etc.

Ultra-Lyte® in gel form has been developed and Clarentis Technologies has commenced testing the efficacy across an array of applications.

Our solutions are proven to be important alternatives to current practices across a spectrum of medical applications and Clarentis Technologies is looking to select pharmaceutical companies to co-develop new products or license our proprietary technology.